Show simple item record

dc.contributor.authorJordan, Allan M
dc.date.accessioned2019-02-08T15:20:10Z
dc.date.available2019-02-08T15:20:10Z
dc.date.issued2018en
dc.identifier.citationJordan AM. Artificial intelligence in drug design-the storm before the calm? ACS Med Chem Lett. 2018 Dec 13;9(12):1150-2.en
dc.identifier.pmid30613315en
dc.identifier.doi10.1021/acsmedchemlett.8b00500en
dc.identifier.urihttp://hdl.handle.net/10541/621542
dc.description.abstractArtificial intelligence in drug design in experiencing a wave of excitement not seen since the emergence of computational chemistry in the late 1980s and early 1990s. Apparently failing to learn the lessons of recent history, we are promised imminent and pervasive solutions to the ills of drug design and significant increases in productivity as we seek to deliver innovative new therapeutics. However, do significant issues remain to be answered before AI enters the day-to-day toolbox of the practicing medicinal chemist?en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1021/acsmedchemlett.8b00500en
dc.titleArtificial intelligence in drug design-the storm before the calm?en
dc.typeArticleen
dc.contributor.departmentDrug Discovery Unit, Cancer Research UK Manchester Institute, The University of Manchester, Alderley Park, Macclesfield, SK10 4TG, UKen
dc.identifier.journalACS Medicinal Chemistry Lettersen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record